Monday, January 14, 2013

And Now, A Word from 2013 DOTY/Alliance Winners ...

The following was submitted by Epizyme EVP/CBO Jason Rhodes. ('Art' by IVB; original)

Among recent elections with profound and far-reaching consequences for national and global affairs, the DOTY is surely...

…well, seriously, Epizyme is truly honored to be recognized by the In Vivo community, particularly among such notable competition. Thank you!

There has never been a better time to be in biotech. The ability to identify true oncogenes and create personalized therapeutics to treat the genetically defined cancers that they drive is a transformational force for patients and all of us. Epizyme is proud to be a leader in this effort.

But it ain’t easy, and it can’t be done alone. Thank you to everyone at our partner Celgene for…

…recognizing the potential of Epizyme’s personalized therapeutics strategy and product platform

… sharing our vision of a partnership that enables us to build a major biopharma company

…and your tremendous commitment to the broader community.

We are thrilled to be working with Celgene and our other partners (not too mention really psyched that we don’t have to worry about our own “fiscal cliff” any time soon!).

Biotech, like that other noble endeavor soccer, is a team sport. Epizyme’s success so far has been made possible by an exceptional group of people in research, development, and business working together. This award is a reflection of their excellence, passion, and willingness to ask (that is, relentlessly hound) friends, family, and strangers met at bars on New Year’s eve to vote, vote, vote!

Along those lines, we’d like to give a special thanks to the Hamilton Wenham Regional High School class of 2015, the bar flies at The Anchor in New Haven, CT and everyone who exercised their franchise. Pericles would be proud.

Congratulations, too, to the winners in the other categories and to all of the nominees, and thanks again to In Vivo and the entire biopharma community. Looking forward to a great 2013!

No comments: